bq-123 and Cerebrovascular-Disorders

bq-123 has been researched along with Cerebrovascular-Disorders* in 2 studies

Other Studies

2 other study(ies) available for bq-123 and Cerebrovascular-Disorders

ArticleYear
Expression of endothelin receptors and nitric oxide synthase in the brain of stroke-prone spontaneously hypertensive rats with cerebral apoplexy.
    Brain research, 1997, May-09, Volume: 756, Issue:1-2

    Endothelin (ET) receptors, ET-1-like immunoreactivity and nitric oxide synthase (NOS) were examined in the brain of stroke-prone spontaneously hypertensive rats (SHRSPs) with cerebral apoplexy. Our receptor autoradiographic method with 125I-ET-1 and unlabeled selective ligands for ET receptors revealed de novo expressions of ET(A) and ET(B) receptors in areas of neural lesions with cerebrovascular damage in SHRSPs. Immunohistochemical staining for ET-1 showed clear ET-1-like immunoreactivity in areas with highly expressed ET receptors. Histochemical studies on astrocytes and microglia suggested that these glial cells, aggregating in lesions, may carry ET receptors, ET-1-like immunoreactivity. Furthermore, NOS detected histochemically using an NADPH-diaphorase staining method was rich on glial cells in damaged areas of the brain in SHRSPs with cerebral apoplexy. Our data suggest the pathophysiological significance of glial ET(A) and ET(B) receptors, ET-1 and NOS in neural lesions of SHRSPs.

    Topics: Animals; Autoradiography; Binding Sites; Brain; Cerebrovascular Disorders; Disease Susceptibility; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Hypertension; NADPH Dehydrogenase; Nitric Oxide Synthase; Peptide Fragments; Peptides, Cyclic; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Endothelin

1997
Effects of a selective endothelin A-receptor antagonist, BQ-123, in salt-loaded stroke-prone spontaneously hypertensive rats.
    Clinical and experimental pharmacology & physiology, 1995, Volume: 22, Issue:10

    1. We examined the effects of a selective endothelin A (ETA)-receptor antagonist, BQ-123, on the development of hypertension and organ damage in stroke-prone spontaneously hypertensive rats (SHRSP) given 1% NaCl for 6 weeks. 2. BQ-123 at doses of 0.7, 2.1 and 7.1 mg/day was continuously administered for 6 weeks to 8 week old salt-loaded SHRSP, who were given water containing 1% NaCl for the following 6 weeks, via a subcutaneous osmotic minipump. 3. Development of high blood pressure was accelerated in salt-loaded SHRSP compared with that in non-salt-loaded SHRSP. After 6 weeks of salt-loading, incidence of cerebral infarction, renal sclerosis and renal fibrosis were greater in salt-loaded than non-salt-loaded SHRSP. 4. BQ-123 attenuated the age-related rise in blood pressure in a dose-dependent manner. The effect coincided with reduction in the incidence of cerebral infarction and prevention of renal sclerosis and fibrosis. Kidney function was improved as observed by an increase in glomerular filtration rate and decreases in urinary protein excretion, blood urea nitrogen and fractional sodium excretion. Furthermore, BQ-123 prevented increases in the heart weight/bodyweight ratio and aortic wall thickness in salt-loaded SHRSP. 5. These results suggest that endogenous endothelin-1 (ET-1) and ETA-receptors may be, at least in part, involved in the pathogenesis of hypertension and organ damage in salt-loaded SHRSP.

    Topics: Animals; Blood Pressure; Blood Urea Nitrogen; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Glomerular Filtration Rate; Hypertension; Infarction; Kidney; Kidney Diseases; Kidney Function Tests; Osmolar Concentration; Peptides, Cyclic; Proteinuria; Rats; Rats, Inbred SHR; Sodium; Sodium, Dietary

1995